Lovastatin changes activities of lactate dehydrogenase A and B genes in rat myocardial cells

Chinese Medical Journal

Volumn 124, Issue 3, 2011, Pages 423-428

  Guo, Wei Zao ^a   Ji, Hong ^a   Yan, Zhi Hong ^a   Li, Lin ^b   Li, Di ^a   Lu, Cui Lian ^a  

^a AEROSPACE CENTRAL HOSPITAL   (China)

^b FUWAI HOSPITAL   (China)

Author keywords

Coronary heart disease; Gene; Lactate dehydrogenase; Lovastatin; Metabolism

Indexed keywords

LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE ISOENZYME 1; LACTATE DEHYDROGENASE ISOENZYME 5; MESSENGER RNA; MEVINOLIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE ACTIVITY; GENE FUNCTION; GENETIC TRANSCRIPTION; HEART MUSCLE CELL; NONHUMAN; RAT; RNA TRANSLATION; TREATMENT DURATION; UPREGULATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BLOTTING, WESTERN; CELL LINE; ISOENZYMES; L-LACTATE DEHYDROGENASE; LOVASTATIN; MYOCYTES, CARDIAC; RATS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 79551713258     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.03.019     Document Type: Article

References (34)

1. Kotlyar AB, Randazzo A, Honbo N, Jin ZQ, Karliner JS, Cecchini G. Cardioprotective activity of a novel and potent competitive inhibitor of lactate dehydrogenase. FEBS Lett 2010; 584: 159-165.
2. Pesek K, Bukovic D, Pesek T, Oreskovic S, Milinovic D, Rukavina M, et al. Risk factor analysis and diagnoses of coronary heart disease in patients with hypercholesterolemia from Croatian Zagorje County. Coll Antropol 2008; 32: 369-374.
3. Markert CL, Moller F. Multiple forms of enzymes: Tissue, ontogenetic, and species specific patterns. Proc Natl Acad Sci U S A 1959; 45: 753-763.
4. Cahn RD, Zwilling E, Kaplan NO, Levine L. Nature and development of lactic dehydrogenases: The two major types of this enzyme form molecular hybrids which change in makeup during development. Science 1962; 136: 962-969.
5. Hsu MY, Kohler MM, Barolia L, Bondar RJ. Separation of five isoenzymes of serum lactate dehydrogenase by discontinuous gradient elution from a miniature ion-exchange column. Clin Chem 1979; 25: 1453-1458.
6. Echigoya Y, Sato T, Itou T, Endo H, Sakai T. Molecular characterization and expression pattern of the equine lactate dehydrogenase A and B genes. Gene 2009; 447: 40-50.
7. Reis GJ, Kaufman HW, Horowitz GL, Pasternak RC. Usefulness of lactate dehydrogenase and lactate dehydrogenase isoenzymes for diagnosis of acute myocardial infarction. Am J Cardiol 1988; 61: 754-758.
8. Huijgen HJ, Sanders GT, Koster RW, Vreeken J, Bossuyt PM. The clinical value of lactate dehydrogenase in serum: a quantitative review. Eur J Clin Chem Clin Biochem 1997; 35: 569-579.
9. Svedruzic ZM, Spivey HO. Interaction between mammalian glyceraldehyde-3-phosphate dehydrogenase and L-lactate dehydrogenase from heart and muscle. Proteins 2006; 63: 501-511.
10. Sylven C, Lin L, Kallner A, Jansson F. Regional distribution of citrate synthase and lactate dehydrogenase isoenzymes in the bovine heart. Acta Physiol Scand 1989; 136: 331-337.
11. Herrmann G, Crotet V, Maly IP, Sasse D. Microquantitative determination of lactate dehydrogenase isoenzymes in the myocardium and the conducting system. Histochem J 1994; 26: 597-600.
12. Matsui Y, Hashimoto H, Tsukamoto H, Okumura K, Ito T, Ogawa K, et al. Disappearance and appearance of isoenzymes of creatine kinase, lactate dehydrogenase and aspartate aminotransferase in the myocardium undergoing infarction. Cardiovasc Res 1989; 23: 249-253.
13. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci U S A 1980; 77: 3957-3961.
14. Alberts AW. Discovery, biochemistry and biology of lovastatin. Am J Cardiol 1988; 62: 10J-15J.
15. Wu X, Lin D, Li G, Zuo Z. Statin post-treatment provides protection against simulated ischemia in bovine pulmonary arterial endothelial cells. Eur J Pharmacol 2010; 636: 114-120.
16. Melchert RB, Liu H, Granberry MC, Kennedy RH. Lovastatin inhibits phenylephrine-induced ERK activation and growth of cardiac. Cardiovasc Toxicol 2001; 1: 237-252.
17. Roelofs AJ, Edwards CM, Russell RG, Ebetino FH, Rogers MJ, Hulley PA. Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3- methylglutaryl-coenzyme A reductase. J Pharmacol Exp Ther 2007; 322: 228-235.
18. Ji H, Guo W, Yan Z, Li D, Lu C. Influence of drug treatment on glucocorticoid receptor levels inpatients with coronary heart disease. Chin Med J 2010; 123: 1685-1689.
19. Roberts R. Diagnostic assessment of myocardial infarction based on lactate dehydrogenase and creatine kinase isoenzymes. Heart Lung 1981; 10: 486-506.
20. Rotenberg Z, Weinberger I, Sagie A, Fuchs J, Sperling O, Agmon J. Lactate dehydrogenase isoenzymes in serum during unstable angina. Clin Chem 1986; 32: 1566-1567.
21. Shahangian S, Ash KO, Wahlstrom NO Jr, Warden GD, Saffle JR, Taylor A Jr, et al. Creatine kinase and lactate dehydrogenase isoenzymes in serum of patients suffering burns, blunt trauma, or myocardial infarction. Clin Chem 1984; 30: 1332-1338.
22. Zammit VA, Newsholme EA. The maximum activities of hexokinase, phosphorylase, phosphofructokinase, glycerol phosphate dehydrogenases, lactate dehydrogenase, octopine dehydrogenase, phosphoenolpyruvatecarboxykinase, nucleoside diphosphatekinase, glutamate-oxaloacetate transaminase and arginine kinase in relation to carbohydrate utilization in muscles from marine invertebrates. Biochem J 1976; 160: 447-462.
23. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976; 72: 323-326.
24. Gunde-Cimerman N, Cimerman A. Pleurotus fruiting bodies contain the inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase-lovastatin. Exp Mycol 1995; 19: 1-6.
25. Liu J, Zhang J, Shi Y, Grimsgaard S, Alraek T, Fonnebo V. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med 2006; 1: 4.
26. Masters BA, Palmoski MJ, Flint OP, Gregg RE, Wang-Iverson D, Durham SK. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131: 163-174.
27. Fukami M, Maeda N, Fukushige J, Kogure Y, Shimada Y, Ogawa T, et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med (Berl) 1993; 193: 263-273.
28. Lamson M, Phillips G, Shen J, Lukacsko P, Friedhoff L, Niecestro RM. Pharmacokinetics of lovastatin extended-release dosage form (Lovastatin XL) in healthy volunteers. Biopharm Drug Dispos 2002; 23: 143-149.
29. Yuan H, Wang F, Tu J, Peng W, Li H. Determination of lovastatin in human plasma by ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. J Pharm Biomed Anal 2008; 46: 808-813.
30. Sylven C, Jansson E, Book K. Key enzymes of myocardial energy metabolism in patients with valvular heart disease: relation to left ventricular function. Acta Physiol Scand 1988; 132: 267-270.
31. Sasso FC, Carbonara O, Nasti R, Campana B, Marfella R, Torella M, et al. Glucose metabolism and coronary heart disease in patients with normal glucose tolerance. JAMA 2004; 291: 1857-1863.
32. Tenenbaum A, Motro M, Fisman EZ, Leor J, Boyko V, Mandelzweig L, et al. Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. Am J Cardiol 2002; 90: 529-532.
33. Jeong D, Kim TS, Lee JW, Kim KT, Kim HJ, Kim IH, et al. Blocking of acidosis-mediated apoptosis by a reduction of lactate dehydrogenase activity through antisense mRNA expression. Biochem Biophys Res Commun 2001; 289: 1141-1149.
34. Ji LL, Stratman FW, Lardy HA. Chronic exercise training alters kinetic properties of rat skeletal muscle and myocardial lactate dehydrogenase. FEBS Lett 1986; 208: 297-300.